<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299962</url>
  </required_header>
  <id_info>
    <org_study_id>803776</org_study_id>
    <secondary_id>P01CA066726</secondary_id>
    <nct_id>NCT00299962</nct_id>
  </id_info>
  <brief_title>Gene Therapy for Pleural Malignancies</brief_title>
  <official_title>A Phase I Clinical Trial of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-beta (BG00001, Ad.hIFN-β for Pleural Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I study will evaluate the safety of two doses of BG00001 at different doses and&#xD;
      intervals. Eligible subjects will have:&#xD;
&#xD;
        -  malignant pleural mesothelioma, or&#xD;
&#xD;
        -  pleural effusions who have progressed through at least one prior therapy or have refused&#xD;
           therapy&#xD;
&#xD;
      BG00001 is given twice through a catheter in the pleural space.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ad.hIFN-β (BG00001) is a replication-defective recombinant adenoviral vector containing the&#xD;
      human interferon-beta (hIFN-β) gene. This Phase I study is designed to evaluate the safety&#xD;
      and maximum tolerated dose (MTD) of two doses of intrapleural (IP) Ad.hIFN-β in subjects with&#xD;
      pleural malignancies either metastatic or pleural mesothelioma.&#xD;
&#xD;
      Five dose levels will be studied:&#xD;
&#xD;
        -  Dose levels 1, 2, and 3 will be given on Days 1 and 15&#xD;
&#xD;
        -  Dose levels 4 and 5 will be given on Days 1 and 8&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine toxicity of two doses of intrapleural BG00001 (Ad.hIFN-β over 8 days, and</measure>
    <time_frame>Through Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess systemic and intrapleural cytokine responses as well as cellular and humoral immune responses after repeated BG00001 instillation,</measure>
    <time_frame>Through Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>and to assess, in a preliminary way, efficacy via tumor regression, time to progression and survival.</measure>
    <time_frame>15 years or until subject dies, whichever comes first</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Pleural Mesothelioma</condition>
  <condition>Metastatic Pleural Effusions</condition>
  <arm_group>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>on Days 1 and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Days 1 and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Days 1 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adenoviral-mediated Interferon-beta</intervention_name>
    <description>BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8</description>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_label>Dose level 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SCH 721015</intervention_name>
    <description>Comparison of different doses and frequency of investigational agent</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_label>Dose level 5</arm_group_label>
    <other_name>Adenoviral-mediated Interferon-beta</other_name>
    <other_name>Ad.hIFN-beta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  must have malignant pleural effusion from mesothelioma or metastatic from primary&#xD;
             lung, breast, gastrointestinal, genitourinary, melanoma, or sarcoma&#xD;
&#xD;
          -  must have evaluable disease&#xD;
&#xD;
          -  must have ECOG performance status of 2&#xD;
&#xD;
          -  must have pleural space involved with tumor accessible for pleural catheter&#xD;
&#xD;
          -  must have FEV1 &gt; 1 liter or 40% of predicted value&#xD;
&#xD;
          -  must have completed radiotherapy and/or treatment with chemotherapy, cytotoxic, or&#xD;
             immunologic agents 4 weeks prior to dosing with BG00001&#xD;
&#xD;
          -  concurrent Tarceva is allowed if patients has been on a stable dose for at least three&#xD;
             months and has not had serious adverse events&#xD;
&#xD;
          -  patients on stable dose of hormone may continue use of hormone&#xD;
&#xD;
          -  patients on stable dose of Tarceva for 3 months and without complications may remain&#xD;
             on Tarceva&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  malignant pleural effusions secondary to lymphoma&#xD;
&#xD;
          -  rapidly re-accumulating, symptomatic malignant pleural effusions that require&#xD;
             immediate mechanical or chemical pleurodesis for palliation&#xD;
&#xD;
          -  untreated brain metastases&#xD;
&#xD;
          -  use of concurrent systemic steroids or immunosuppressants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel H. Sterman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.marf.org</url>
    <description>mesothelioma research foundation</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 3, 2006</study_first_submitted>
  <study_first_submitted_qc>March 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2006</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gene therapy</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

